Vamorolone

Drug Profile

Vamorolone

Alternative Names: VB-15; VBP-15

Latest Information Update: 07 Feb 2017

Price : $50

At a glance

  • Originator ReveraGen BioPharma
  • Developer National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Neurological Disorders and Stroke; ReveraGen BioPharma; University of Pittsburgh
  • Class Anti-inflammatories; Antianaemics; Antiasthmatics; Corticosteroids; Glucocorticoids; Pregnatrienes; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy
  • Phase I Asthma; Cystic fibrosis; Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis; Sickle cell anaemia
  • Discontinued Amyotrophic lateral sclerosis; Spinal muscular atrophy

Most Recent Events

  • 01 Feb 2017 ReveraGen BioPharma plans a phase II trial for Duchenne muscular dystrophy in Australia, Canada, Israel, Sweden, United Kingdom and the USA (NCT03038399)
  • 07 Nov 2016 ReveraGen BioPharma plans a phase IIb trial for Duchenne Muscular Dystrophy
  • 03 Nov 2016 Actelion obtains an option to in-license vamorolone for Duchenne muscular dystrophy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top